Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$-2.56
EPS est.
$-2.58
EPS surprise
+0.88%
1-day move
-0.98%
BioNTech's earnings report shows a larger-than-expected loss per share, which may raise concerns among investors. The stock reacted by declining nearly 1% following the announcement. The lack of revenue and guidance updates adds uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.56 | $-2.08 | +0.88% |
| Revenue | — | $156M | — |
No transcript is on record, and the analysis is based on numerical results only.
BioNTech SE is a biotechnology company focused on developing innovative therapies and vaccines, particularly in the field of immunotherapy. With a market cap of $23 billion, it plays a significant role in the health care sector, especially following its success with COVID-19 vaccines.
Last quarter
In Q1 2026, BioNTech reported an EPS of $-2.28, which was better than analysts' expectations. However, the stock fell 3.88% the following day, indicating market disappointment.
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
+18.51%
Avg 1-day reaction
-3.66%
Analysts expect BioNTech to report losses again this quarter, with a consensus EPS of $-2.08 and revenue of $156 million. The market is closely watching for any signs of recovery or growth.
Bull case
If BioNTech can exceed revenue expectations and show signs of a path to profitability, it could boost investor confidence and drive the stock price higher.
Bear case
Continued losses and lower-than-expected revenue could lead to further declines in the stock, especially if the company fails to provide a clear turnaround strategy.
Key metrics to watch
EPS
$-2.08Earnings per share is a key indicator of profitability, and this quarter's consensus suggests continued losses.
Revenue
$156MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the revenue exceed the consensus estimate of $156 million?
Revenue performance is critical for assessing the company's market demand and growth potential, especially after recent losses.
Q2
What is the outlook for profitability given the expected EPS of $-2.08?
Understanding management's strategy for returning to profitability will be crucial for investor confidence and stock performance.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The consensus is overly pessimistic about revenue growth, as recent partnerships and product developments could drive better-than-expected sales.
Supporting evidence
The company has a history of surprising on the upside, with a 63% EPS beat rate over the last eight quarters.
Options are pricing in a larger move than the historical average, indicating potential for a significant surprise.
Recent developments in their pipeline may not be fully reflected in current revenue expectations.
Key risk
If revenue comes in above $200 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's results are pivotal for determining whether BioNTech can stabilize its financial performance after a series of losses.
Bull confirmed if
A revenue figure above $200 million would indicate strong market demand and could confirm a bullish outlook.
Bear confirmed if
An EPS worse than $-3.08 would reinforce concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±10.69%
Historical Avg
±4.3%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±10.7% while BNTX has averaged ±4.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
37.4%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$27.1M
278,000 sh
1 insider
Net
$27.1M
Net selling
Most Active Insiders· 9 open-market trades
$27.1M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
20.45%
of float
Insider
57.24%
of float
Holders
476
institutions
Top Holders· as of Jun 2026
FMR, LLC
7,571,805 sh · $721.2M
2.99%
32.6%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If BioNTech beats expectations, history suggests the stock could see a modest increase of around 2.09% on the first day.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A disappointing report could lead to a decline of approximately 7.43%, reflecting ongoing investor concerns.
The lines on the call that would change the story.
Recent Transactions
Oct 5, 2026 · @ $97.23
72,000 sh
$7.0M
Sep 28, 2026 · @ $98.47
34,000 sh
$3.3M
Sep 29, 2026 · @ $98.26
34,000 sh
$3.3M
Sep 30, 2026 · @ $98.12
32,000 sh
$3.1M
Sep 25, 2026 · @ $98.69
27,000 sh
$2.7M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Primecap Management Company
3,772,031 sh · $359.3M
1.49%
-0.6%
Dodge & Cox Inc.
3,677,591 sh · $350.3M
1.45%
0.0%
Flossbach von Storch SE
2,226,138 sh · $212.0M
0.88%
-39.5%
T. Rowe Price Investment Management, Inc.
2,065,456 sh · $196.7M
0.82%
-64.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.